tel: 646-342-6186


  • J.D., Fordham University School of Law, 2002 (Dean's list)
  • Ph.D., Biochemistry and Molecular Biology, Harvard University, 1994
  • M.S., Biology, California State University, 1986 (with honors)
  • B.S., Microbiology and Immunology, McGill University, 1981

Bar and Courts

  • New York
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • U.S. Patent and Trademark Office
  • Supreme Court of the United States


  • Chinese
  • Spanish

Stanley Liang is one of the founders of the firm and comes to the firm after gaining more than 22 years of patent law experience in some of the best patent law firms in New York, including Fish & Neave LLP (now Ropes & Gray LLP) and Kenyon & Kenyon LLP.

Dr. Liang provides patent law service to clients, big and small, majority of whom are in the biotechnology and pharmaceutical industries.

Dr. Liang has a broad intellectual property law practice, including:

  • patent preparation and prosecution
  • inter-parte and post-grant review
  • freedom-to-operate, due diligence and patentability analysis and opinion
  • interference, litigation, and opposition

Dr. Liang has prepared and prosecuted an array of US and foreign patent applications relating to the biological, chemical, biophysical and mechanical arts, on technologies including:

  • stem cells
  • gene therapy
  • antibodies
  • disease related genes and proteins
  • proteomics
  • vaccines
  • formulations
  • polymorphs
  • small molecules
  • medical device
  • consumer products
Representative cases include the following interferences:
  • Sugano (Japan Foundation for Cancer Research) v. Goeddel (Genentech)
  • Noelle v. Lederman (Biogen), 355 F. 3d 1343 (Fed. Cir. 2004)
  • Biochem Pharma, Inc. v. Emory University
  • Badger (subsidiary of ExxonMobil) v. Antofina
  • University of Sherbrooke v. National Jewish Medical and Research Center.
Representative cases include the following patent litigations:
  • Biochem Pharma, Inc. v. Emory University (D. D.C.)
  • Biogen v. Berlex 318 F.3d 1132 (Fed. Cir., 2003)
  • Housey v. Astrazeneca et al. 366 F.3d 1348 (Fed. Cir. 2004)
  • Braun GmbH v. Rayovac Corp. (D. Mass.)
  • Penwest and Endo v. Impax (D. N.J.)
  • Infosint v. Lunbeck and Forest (S.D.N.Y.)
  • Medeva v. Roxane (D. N.J.)
  • Pfizer v. Teva (D. N.J.)
  • Colleen Superko and Stanley Liang, Don't Leave Money on the Table: Run an IP Audit, Mass High Tech, October 19, 2007 issue
  • Pierri, M.A. and Liang. S.D., Making a Difference with the Written Description, New York Law Journal, April 10, 2006 issue
  • Liang, S.D., Marmorstein, R, Harrison, S.C., and Ptashne, M., DNA Sequence Preferences of GAL4 and PPR1: How a subset of Zn2Cys6 Binuclear Cluster Proteins Recognizes DNA, Molecular and Cellular Biology16: 3773-3781 (1996).
  • Yie, J.M., Liang, S. (co-first author), Merika, M., and Thanos, D., HMG I Binds to DNA via Novel Mechanisms Requiring Both Inter- and Intra-molecular Cooperativity, Molecular and Cellular Biology: 17(7):3649-62 (1997).
  • Simeonidis, S., Liang S. (co-first author), Chen, G., and Thanos D., Cloning and functional characterization of mouse IkappaB epsilon, Proc Natl Acad Sci USA, 94: 14372-7 (1997).